← 返回 Skills 市场

Crispr Therapeutics

Name: Crispr Therapeutics
Author: hanxueyuan

作者 hanxueyuan · GitHub ↗ · v1.0.0 · MIT-0

cross-platform ✓ 安全检测通过

总下载

当前安装

版本数

在 OpenClaw 中安装

/install crispr-therapeutics

功能描述

CRISPR Therapeutics develops CRISPR-Cas9 gene editing therapies, including FDA-approved Casgevy for sickle cell disease, partnering with Vertex Pharmaceuticals.

使用说明 (SKILL.md)

CRISPR Therapeutics

发展历程

2013: Emmanuelle Charpentier和Emmanuelle de Silva在瑞士创立
2015: 与Vertex Pharmaceuticals建立战略合作
2016: 10月在纳斯达克上市
2018: 启动CTX001(镰状细胞病)临床试验
2019: CTX001数据显示治愈率近100%
2020: Charpentier获诺贝尔化学奖(CRISPR基因编辑)
2023: Casgevy获FDA批准，成为全球首个CRISPR基因编辑疗法
2024: 与Vertex扩大合作，推进肿瘤学和自身免疫疾病管线

核心业务

CRISPR基因编辑疗法开发 + 与大型药企(如Vertex)的合作授权收入 + 内部管线推进

竞争优势

CRISPR-Cas9核心专利组合(与Broad Institute交叉授权)、首个获批疗法的临床验证、与Vertex的深度绑定、创始团队的诺贝尔奖声誉

关键指标

Casgevy定价$220万美元/疗程；与Vertex合作获得超$10亿里程碑付款；2024年市值约$50亿

故事

Casgevy是医学史上第一个使用CRISPR'基因剪刀'技术获批的疗法——它从患者体内取出造血干细胞，用CRISPR精确编辑后重新注入患者体内，从根本上治愈了镰状细胞病。治疗只需一次，但定价高达220万美元

安全使用建议

This skill appears safe from a security perspective because it is an instruction-only informational reference. Users should still independently verify biomedical and investment-related facts before relying on them for medical, financial, or business decisions.

功能分析

Type: OpenClaw Skill Name: crispr-therapeutics Version: 1.0.0 The skill bundle contains purely informational content regarding CRISPR Therapeutics, including its history, business model, and clinical milestones. There is no executable code, network activity, or malicious instructions within SKILL.md or _meta.json.

能力评估

✓ Purpose & Capability

The artifact is coherent with the stated purpose: it provides background information about CRISPR Therapeutics, its therapies, partnerships, and market context.

✓ Instruction Scope

The skill contains reference content and read_when triggers only; it does not instruct the agent to override user intent, run tools, access accounts, or take actions.

✓ Install Mechanism

There is no install specification, no code, no dependencies, and no required binaries.

✓ Credentials

No environment variables, credentials, files, network access, or local system capabilities are requested.

✓ Persistence & Privilege

The artifacts show no persistence, background execution, privileged access, memory use, or account authority.

如何使用

确保已安装 OpenClaw（本地或 Docker 部署）
在对话框中输入安装命令：/install crispr-therapeutics
安装完成后，直接呼叫该 Skill 的名称或使用 /crispr-therapeutics 触发
根据 Skill 的参数说明提供必要输入，即可获得结构化输出

版本历史

v1.0.0

- First public release of the CRISPR Therapeutics skill - Provides company background, major milestones, and business overview - Highlights CRISPR-Cas9's clinical and regulatory achievements, including the 2023 FDA approval of Casgevy - Covers competitive advantages, financial metrics, and collaboration details - Useful for understanding the commercialization and market impact of CRISPR gene editing therapies

元数据

Slug crispr-therapeutics

版本 1.0.0

许可证 MIT-0

累计安装 0

当前安装数 0

历史版本数 1

常见问题